- Home
- FF vs LUNG Comparison
FF vs LUNG Comparison
Compare FF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FF
- LUNG
- Stock Information
- Founded
- FF N/A
- LUNG 1995
- Country
- FF United States
- LUNG United States
- Employees
- FF N/A
- LUNG N/A
- Industry
- FF Major Chemicals
- LUNG Industrial Specialties
- Sector
- FF Industrials
- LUNG Health Care
- Exchange
- FF Nasdaq
- LUNG Nasdaq
- Market Cap
- FF 230.8M
- LUNG 251.5M
- IPO Year
- FF N/A
- LUNG 2020
- Fundamental
- Price
- FF $5.09
- LUNG $6.23
- Analyst Decision
- FF Strong Buy
- LUNG Buy
- Analyst Count
- FF 1
- LUNG 6
- Target Price
- FF $0.80
- LUNG $11.92
- AVG Volume (30 Days)
- FF 258.1K
- LUNG 242.6K
- Earning Date
- FF 11-08-2024
- LUNG 02-19-2025
- Dividend Yield
- FF 4.71%
- LUNG N/A
- EPS Growth
- FF 24.25
- LUNG N/A
- EPS
- FF 0.82
- LUNG N/A
- Revenue
- FF $273,839,000.00
- LUNG $79,302,000.00
- Revenue This Year
- FF N/A
- LUNG $22.26
- Revenue Next Year
- FF N/A
- LUNG $18.72
- P/E Ratio
- FF $6.27
- LUNG N/A
- Revenue Growth
- FF N/A
- LUNG 22.34
- 52 Week Low
- FF $4.15
- LUNG $5.46
- 52 Week High
- FF $8.36
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- FF 44.22
- LUNG 41.37
- Support Level
- FF $5.09
- LUNG $5.72
- Resistance Level
- FF $5.35
- LUNG $6.28
- Average True Range (ATR)
- FF 0.13
- LUNG 0.40
- MACD
- FF 0.02
- LUNG -0.03
- Stochastic Oscillator
- FF 41.94
- LUNG 19.85
About FF FutureFuel Corp. Common shares
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.